News >

Novel Combos Raise Sequencing Questions in Nonsquamous NSCLC

Caroline Seymour
Published: Tuesday, Aug 13, 2019

Rathi N. Pillai, MDD

Rathi N. Pillai, MD
With superior response rates, progression-free survival (PFS), overall survival (OS) and little additive toxicity to chemotherapy alone, chemoimmunotherapy combinations have become a new standard of care in the frontline treatment of patients with advanced nonsquamous non–small cell lung cancer (NSCLC), said Rathi N. Pillai, MD. However, their widespread adoption has also raised an abundance of questions in the second-line setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication